Trial Profile
A Multi-center, Open Label Trial, to Show Efficacy and Safety of 4.0 mg.Kg-1 Sugammadex Administered at a Depth of Neuromuscular Blockade of 1-2 PTC Induced by Rocuronium in Chinese and European ASA I-III Subjects Undergoing Elective Surgery Under Propofol Anesthesia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 26 Sep 2014 New trial record